A comprehensive analysis section that covers unveiling insights about Blueprint Medicines Corporation's gradings, price targets and earnings estimates.
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
E | E | E | E | E | E | |||||||
2015 | - | -2.165 | - | 8 | - | -131 | - | -6 | - | -6 | - | 9 |
2016 | -2.8900 | -2.690 | 11 | 26 | -52 | -162 | -52 | -18 | -51 | -18 | 14 | 26 |
2017 | -2.6400 | -3.793 | 27 | 24 | -72 | -134 | -72 | -133 | -72 | -137 | 19 | 25 |
2018 | -3.9200 | -5.333 | 21 | 45 | -148 | -228 | -147 | -223 | -151 | -238 | 27 | 45 |
2019 | -5.3900 | -7.575 | 44 | 41 | -236 | -359 | -236 | -354 | -247 | -373 | 47 | 42 |
2020 | -6.8700 | 5.491 | 66 | 788 | -328 | 71 | -361 | 76 | -361 | 66 | 96 | 142 |
2021 | 5.7600 | -6.272 | 793 | 176 | 313 | -494 | 308 | -486 | 308 | -493 | 157 | 163 |
2022 | -11.0100 | -9.346 | 180 | 199 | -644 | -517 | -641 | -507 | -641 | -514 | 195 | 179 |
2023 | -9.3500 | -8.581 | 204 | 245 | -557 | -506 | -537 | -566 | -537 | -574 | 237 | 209 |
2024 | -8.3700 | -0.965 | 249 | 508 | -506 | -58 | -474 | -366 | -486 | -368 | 295 | 516 |
2025 | - | -0.883 | - | 712 | - | -83 | - | -514 | - | -516 | - | 723 |
2026 | - | 1.722 | - | 949 | - | 2.F11X | - | 2.F111 | - | 2.F1111 | - | 2.F1111 |
2027 | - | 3.998 | - | 1,167 | - | 1.F12X | - | 1.F121 | - | 1.F1211 | - | 1.F1211 |
2028 | - | 5.591 | - | 1,316 | - | 0.F13X | - | 0.F131 | - | 0.F1311 | - | 0.F1311 |